Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CERTIS1: AZD9574 Monotherapy and Combinations in Advanced Solid Malignancies
NCT05417594Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Jun 2022
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of palacaparib in solid tumor, ovarian cancer, breast cancer, pancreatic cancer (PC), prostate cancer (PCa), sponsored by AstraZeneca. Started Jun 2022; status: recruiting.
02
Drugs
palacaparib
03
Conditions
solid tumorovarian cancerbreast cancerpancreatic cancer (PC)prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05417594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05417594.